Are Peptides Legal? US, UK and Australia Explained

"Peptides" covers everything from FDA-approved drugs to vials sold with a "not for human consumption" sticker, and the law treats those very differently. This guide sets out the US, UK and Australian rules as they stood in September 2026, with the official source behind each statement. It is general information, not legal advice.

Short answer: it depends on which peptide and how it is sold. Peptides approved as medicines, such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and tesamorelin (Egrifta), are legal with a prescription in the US^9,10,11. Most peptides sold online (BPC-157, TB-500, CJC-1295, ipamorelin and similar) are not approved drugs anywhere in these three countries. As of September 2026, US pharmacies still cannot lawfully compound them⁷. The UK prohibits selling or supplying unauthorised medicinal products¹². Australia lists them as prescription-only and makes possessing them without authority illegal¹⁶. A "research use only" label changes none of this⁸.

This guide describes regulations as of September 2026. It is not legal advice, and the rules for specific peptides are changing, particularly in the US. For the safety evidence on individual compounds, see are peptides safe?

Peptide legal status at a glance

United States: prescription drugs, compounding and the 503A bulks list

FDA-approved peptide drugs

Some peptides went through FDA approval and are sold as prescription medicines with a label that defines their dose and use. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are examples^9,10, and so is tesamorelin. Egrifta WR is a growth hormone releasing hormone (GHRH) analog indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, and its label states it "is not indicated for weight loss"¹¹. Approval covers the labelled use of the approved product. It does not cover a copy of the same molecule bought somewhere else.

What pharmacies may compound

Section 503A of the Federal Food, Drug, and Cosmetic Act lets state-licensed pharmacies compound for an identified patient with a valid prescription. The bulk drug substance has to meet one of three conditions: it complies with a USP or National Formulary monograph; if there is no monograph, it is a component of an FDA-approved drug; or, if neither, it appears on a list FDA develops through regulations, known as the 503A bulks list¹. Most wellness peptides have no monograph and are not part of any approved drug, so the bulks list is the only way they can become legal to compound.

While FDA works through nominations to that list, it uses an interim policy that sorts nominated substances into categories. For Category 1 substances, FDA has said it does not intend to act against pharmacies that compound with them while evaluation continues². Category 2 holds substances FDA says "may present significant safety risks"³. A January 2025 revision of the policy ended the category system for substances nominated after that date².

FDA's Category 2 page shows several peptides added on 29 September 2023 and still listed: kisspeptin-10 under the 503A policy, and GHRP-2, GHRP-6 and ipamorelin acetate under the parallel 503B policy for outsourcing facilities. For these, FDA cites immunogenicity risk, impurities, and in some cases reports of serious adverse events³. FDA's page lists another group of peptides that were "previously in category 2" and whose nominations "were withdrawn by the nominators". That group includes AOD-9604, BPC-157, CJC-1295, GHK-Cu for injection, Melanotan II, MOTS-c, Selank, Semax, thymosin alpha-1 and TB-500. The page still records a safety concern for each one, such as immunogenicity, missing human exposure data, and for Melanotan II, case reports of melanoma, encephalopathy and priapism³. As regulatory lawyers note, none of these peptides was ever in Category 1, so none was ever eligible for lawful 503A compounding⁴.

The July 2026 advisory committee votes

On 23–24 July 2026, FDA's Pharmacy Compounding Advisory Committee considered seven peptides for the 503A bulks list, each for specific uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide (DSIP) for opioid withdrawal, chronic insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia⁵.

According to STAT's reporting, FDA staff recommended against every one of these peptides because clinical evidence of safety and efficacy was lacking⁶. Advisory committees give non-binding advice⁵. Any listing would be published as a proposed rule with a public comment period⁶. A law-firm analysis dated 4 August 2026 put it this way: "as of this writing, these peptides still cannot be lawfully compounded, and FDA can continue to take enforcement action against compounding pharmacies that make these peptides"⁷. FDA has also announced a second committee meeting before February 2027 on GHK-Cu, Melanotan II, LL-37, dihexa and PEG-MGF⁴. Being on the bulks list would not make any of these an FDA-approved drug. It would only allow a pharmacy to compound them on prescription.

"Research use only" and "not for human consumption"

Many online sellers describe their vials as research chemicals. FDA has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide "falsely labeled 'for research purposes' or 'not for human consumption'". It also states that retatrutide and cagrilintide "cannot be used in compounding under federal law"⁸. The label does not change what the product legally is. A product sold to be injected by people is treated as an unapproved drug.

Growth hormone has its own statute. Knowingly distributing human growth hormone (somatropin, somatrem or an analogue), or possessing it with intent to distribute, for any human use other than an FDA-authorized use on a physician's order carries up to 5 years in prison, or 10 if a minor is involved¹⁷. Growth hormone secretagogues and GHRH analogues are different molecules and are not named in that provision. They fall under the drug approval and compounding rules above.

United Kingdom

In the UK, the key rule is regulation 46 of the Human Medicines Regulations 2012: "A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product"¹². Peptides without a UK marketing authorisation, such as BPC-157 and TB-500, have no lawful route to being sold as a medicine. Enforcement is active. On 29 May 2026, the MHRA announced two arrests and its largest ever seizure of unlicensed weight-loss medicines: around 12,000 doses including retatrutide and tirzepatide, along with "peptide products". The investigation was into offences under the 2012 Regulations¹⁵.

Some peptide hormones are also controlled drugs. Part III of Schedule 2 of the Misuse of Drugs Act 1971 lists somatotropin, somatrem, somatropin, chorionic gonadotrophin (HCG) and non-human chorionic gonadotrophin as Class C, alongside anabolic steroids such as testosterone and nandrolone¹³. The government's penalty guidance sets Class C supply and production at up to 14 years. It says it is "not an offence" to possess anabolic steroids for personal use¹⁴. That exception is written for anabolic steroids. We could not find an official source that applies it to the peptide hormones in the same list, so we don't assume it does. Most synthetic "research" peptides are not named in the 1971 Act at all, and they are regulated as medicines instead.

Australia

Australia's Poisons Standard (June 2026 instrument) lists BPC-157, TB-500, thymosin beta-4, CJC-1295, ipamorelin, AOD-9604, growth hormone releasing peptides including GHRP-6 and pralmorelin (GHRP-2), and somatropin in Schedule 4, as prescription only medicines¹⁶. They also appear in Appendix D, clause 5, which lists "poisons for which possession without authority is illegal", for example possession other than under a legal prescription. The same clause covers anabolic steroidal agents, SARMs, growth hormone secretagogues, ibutamoren and hexarelin¹⁶. Semaglutide and tirzepatide are in Schedule 4 as well¹⁶. Of the three countries here, Australia is the only one where simply possessing BPC-157 without a prescription is illegal under the national scheduling instrument.

The Poisons Standard sets national scheduling. States and territories apply it through their own laws, and import permits are handled separately. We could not load the TGA's own guidance pages to verify its advice on importing and compounding, so this section relies only on the legislative instrument itself.

Athletes: the WADA Prohibited List

Sport has its own rules, and they apply whether or not a substance is legal where you live. The 2026 WADA Prohibited List took effect on 1 January 2026¹⁸. Its S0 category bans at all times any substance with "no current approval by any governmental regulatory health authority for human therapeutic use", and it names BPC-157 as an example¹⁸. S2 bans at all times growth hormone and its fragments (including AOD-9604), GHRH and its analogues (CJC-1293, CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (including ibutamoren and ipamorelin), GHRPs (including GHRP-2, GHRP-6 and hexarelin), and thymosin-β4 and its derivatives such as TB-500¹⁸. Tesamorelin shows why prescription status doesn't help here: it is an approved drug in the US and is still banned in sport. Athletes with a medical need use the therapeutic use exemption process.

What this means in practice

1. Check whether your peptide is an approved medicine in your country. If it is, the legal route is a prescription for the approved product.
2. In the US, check whether a compounded version rests on a monograph, an approved-drug component, or a final 503A bulks listing. As of September 2026, BPC-157 and the other July 2026 candidates rest on none of these.
3. Don't rely on "research use only" wording. Regulators in all three countries judge a product by how it is sold and used, not by its sticker.
4. If you are tested under the WADA Code, check the Prohibited List first. S0 and S2 bans apply out of competition too.
5. For anything specific to your situation, ask a lawyer or your national regulator. This page is a dated summary, not advice.

Legality and safety are separate questions. A peptide can be legal and poorly studied, or banned and well studied. For the safety side, see are peptides safe?

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. 21 U.S.C. § 353a — Pharmacy compounding (Federal Food, Drug, and Cosmetic Act § 503A). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/353a
2. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability. Federal Register. 90 FR 1137, January 7, 2025. https://www.govinfo.gov/content/pkg/FR-2025-01-07/html/2024-31546.htm
3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
4. Snow CD, Palmer KL. FDA's Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2). FDA Law Blog, Hyman, Phelps & McNamara. April 21, 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
5. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Content current as of August 6, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
6. Lawrence L, Todd S. FDA advisory panel narrowly rejects compounding of one peptide, backs two others. STAT. July 24, 2026. https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
7. Werner MJ, Klock SM. FDA Advisory Committee Endorses Compounding of Certain Peptides. Holland & Knight Alert. August 4, 2026. https://www.hklaw.com/en/insights/publications/2026/08/fda-advisory-committee-endorses-compounding-of-certain-peptides
8. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of September 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
9. Novo Nordisk. WEGOVY (semaglutide) injection and tablets — Prescribing Information (revised June 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
10. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — Prescribing Information (revised August 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
11. U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin for injection) — Full Prescribing Information. accessdata.fda.gov. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
12. The Human Medicines Regulations 2012 (SI 2012/1916), regulation 46: Requirement for authorisation. legislation.gov.uk. https://www.legislation.gov.uk/uksi/2012/1916/regulation/46
13. Misuse of Drugs Act 1971, Schedule 2 (Controlled drugs), Part III: Class C drugs. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2
14. GOV.UK. Drugs penalties. https://www.gov.uk/penalties-drug-possession-dealing
15. Medicines and Healthcare products Regulatory Agency. Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. GOV.UK. May 29, 2026. https://www.gov.uk/government/news/two-arrested-during-the-mhras-largest-ever-seizure-of-unlicensed-weight-loss-medicines
16. Australian Government Department of Health, Disability and Ageing. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, Schedule 4 and Appendix D clause 5. Federal Register of Legislation, F2026L00633, registered May 28, 2026. https://www.legislation.gov.au/F2026L00633/asmade
17. 21 U.S.C. § 333(e) — Penalties: prohibited distribution of human growth hormone. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/333
18. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026 (in force January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf